{"prompt": "['Amended Clinical Trial Protocol NO 03', '18-Apr-2018', 'ACT14656', 'Version number: 1', '1.4', 'DAY 1 FLOW CHART', '1.4.1 Flow chart with PET scan on Day 1 (not applicable for patients diagnosed with MVA and stable angina without previous PCI and', 'with previous coronary artery angiography or CCTA between 24 months and 5 years prior to screening, who', 'need', 'CCTA', 'during', 'screening period)', 'Day', 'D1', 'Time (hour/minute)', '-4H', '-3H', '-2H30', '-0H30', 'OH', '1H', '3H', 'Visit start', 'X', 'End of visit', 'Concomitant medicationsb', '\u20ac', 'SAQ', 'X', 'Resources Utilization', 'X', \"Patients' perception of treatment and symptoms\", 'X', \"Patient's diary\", '\u20ac', 'Inclusion/Exclusion criteria', 'X', 'X', 'CFR assessed by vasodilator stress PET scanC', 'xd', 'NIMP administration', 'xh', 'IVRS/IWRS', 'X', 'Randomization', 'IMP administration', 'X', 'Safety', 'Physical examination', 'X', 'Body temperature', 'X', 'Body weight', 'X', 'Property of the Sanofi Group - strictly confidential', 'Page 16', '(electronic 4.0)']['Amended Clinical Trial Protocol NO 03', '18-Apr-2018', 'ACT14656', 'Version number: 1', 'Day', 'D1', 'Time (hour/minute)', '-4H', '-3H', '-2H30', '-0H30', 'OH', '1H', '3H', 'Vital signs9, 12 lead-ECG', 'X', 'X', 'X', 'X', 'Hematology, biochemistry, urinalysis', 'X', 'Renal function (blood creatinine/, and cystatin C)', 'X', 'Adverse event collection', '\u20ac', 'Pharmacokinetics', 'SAR407899 plasma samples', 'X', 'X', 'DNA', 'Pharmacogenetic DNA sample', 'X', 'Biomarkers', 'Blood samples for', 'and', 'X', 'Future use of samples', 'Blood sample if specific consent signed', 'X', 'DME = drug metabolizing enzymes; ECG = electrocardiogram; IMP = investigational medicinal product.', 'Note: when several items take place at the same time, the following order should be respected: questionnaires, ECG,vital signs,blood sampling, pharmacodynamics, drug administration, meal.', 'In order to respect exact timing of pharmacokinetic samples, the other measures will be done ahead of the scheduled time.', 'a Time (hour/minute) is expressed in reference to the first administration of SAR407899 (TOH). The times expressed prior to TOH are', 'approximate.', 'b Concomitant medication (if those are not allowed during the study, see exclusion criterion 3 in Section 7.2.1) needs to be stopped 1 week before CFR assessed by PET scan.', 'C Restriction rules for CFR assessed by vasodilator stress PET scan (detailed in Section 10.1.2) to follow.', 'd Prior to the Day 1 PET assessment, the eligibility criteria must be carefully reviewed (including review of the screening labs), and if the patient no longer qualifies for the study, then he/she should not undergo the', 'PET assessment.', 'e Refer to Safety Section 9.2 for detailed safety investigations.', 'f', 'Vital signs should be performed by the investigator or designee. Continuous monitoring of heart rate, BP and 12-lead ECG should be performed throughout the stressor infusion.', 'g Vital signs: BP & heart rate measurements including search of hypotension (orthostatic or not).', 'h Only for PET scan.', \"i The patient may be discharged later on Day 1 to guarantee patient's safety based upon the opinion of the Investigator.\", 'j', 'Mandatory to check criterion E 25. Alternatively for practical reasons, blood creatinine results should be obtained within 2 days prior to Day 1 to check the exclusion criterion E25.', 'Property of the Sanofi Group - strictly confidential', 'Page 17', '(electronic 4.0)']['Amended Clinical Trial Protocol NO 03', '18-Apr-2018', 'ACT14656', 'Version number: 1', '1.4.2 Flow chart with PET scan prior to Day 1', 'This flow chart is displayed as follows:', '-', 'PET scan up to 28 days if patient with MVA and stable angina without previous PCI and with previous coronary', 'artery', 'angiography', 'or', 'CCTA between 24 months and 5 years prior to screening', '-', 'or PET scan up to 14 days prior to D1 if previous coronary artery angiography or CCTA within 24 months prior to screening', 'Day', 'PET scan up to 28 days or up to', 'D1', '14 days', 'Time (hour/minute)', 'Prior dosing', 'OH', '1H', '3H', 'Visit start', 'X', 'X', 'End of visit', 'X', 'Concomitant medicationsb', '\u20ac', 'SAQ', 'X', 'Resources Utilization', 'X', \"Patients' perception of treatment and\", 'X', 'symptoms', \"Patient's diary\", '\u20ac', 'Inclusion/Exclusion criteria', 'X', 'X', 'CFR assessed by vasodilator stress', 'xd', 'PET scan c,f', 'NIMP administration', 'x', 'IVRS/IWRS', 'X', 'Randomization', 'X', 'IMP administration', 'X', 'Property of the Sanofi Group - strictly confidential', 'Page 18', '(electronic 4.0)']\n\n###\n\n", "completion": "END"}